Royalty Report: Drugs, Disease, Diagnostic – Collection: 203549

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Disease
  • Diagnostic
  • Therapeutic
  • Vaccine
  • Drug Discovery
  • Viral Infection
  • Antibiotic
  • HIV / AIDs
  • Cancer
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203549

License Grant
For the technology, Licensor grants the Licensee of Bermuda, an exclusive, even as to Licensor, worldwide, sub-licensable license, under the Licensors Technology, to develop, make, have made, use, sell, have sold, offer for sale and import the Licensors Compounds and Products in the Primary Fields; and to develop, make and have made the Licensors Compounds and Products in the ID Field, but without any right to sell or commercialize in the ID Field. Licensee may sublicense the rights granted.

Each Party hereby grants to the other Party a non-exclusive, non-sublicensable (except to Affiliates) license to its Patent Rights and Know-How solely to the extent necessary to permit such other Party to perform its responsibilities relating to the Anadys Compound or Product under the Development Plan during the term of this Agreement.

License Property
The product is any product incorporating or comprising the Lead Compound or any other Licensors Compound in finished dosage pharmaceutical form, including, in each case, all formulations and modes of administration thereof, the development, manufacture, sale or use of such Lead Compound or other Licensor Compound would, but for the license granted hereunder, infringe the Licensor Patent Rights or incorporates or embodies Licensor Know-How.

The licensing and co-development agreement is for the development and potential commercialization of ANA975 and potentially additional Toll-Like Receptor (“TLR7”) oral prodrugs for chronic hepatitis C virus (“HCV”) and hepatitis B virus (“HBV”) infections, as well as other potential infectious disease indications.

ANA975, a 5-amino-3-ß -D-ribofuranosyl-3H-thiazolo[4,5-d]pyrimidin-2-one derivative, was synthesized in the search of an oral prodrug of isatoribine, a small molecule toll-like receptor 7 (TLR-7) agonist.

Toll-like receptor 7, also known as TLR7, is a protein that in humans is encoded by the TLR7 gene.

Field of Use
The primary field is the HCV Field and HBV Field. Primary field shall mean either the HCV Field or the HBV Field, as applicable.

ID field means the treatment, diagnosis or prevention of infectious diseases outside of the Primary Fields.

HBV field means the treatment, diagnosis or prevention of hepatitis B virus (HBV).
HCV field means the treatment, diagnosis or prevention of hepatitis C virus (HCV).

IPSCIO Record ID: 277105

License Grant
For outside the licensed field, Licensor grants a worldwide, non-exclusive, and sublicenseable right and license to practice Licensors rights in Joint Collaboration Patent Rights to make, have made, import, promote, market, distribute or sell Licensee Products outside the Licensed Field.

This agreement contains both exclusive and non-exclusive grants between the parties.

License Property
The Patent Rights and Know-How are pertaining to the PADRE® Technology.

Licensed Product shall mean a therapeutic or prophylactic vaccine the manufacture. use or sale of which, but for any license granted to Licensee herein, would infringe a Valid Claim of one or more Licensor Patent Rights or one or more Collaboration Patent Rights, or was developed or manufactured using Licensor Know-How.

PADRE® Technology shall mean a family of immunostimulatory molecules which when combined with cytotoxic T cell epitopes increase the magnitude and duration of the immune response.

Field of Use
Licensed Field shall mean the research, development and commercialization of Licensed Products for treating or preventing diseases associated with the following viruses HPV. HBV and HCV.  HBV shall mean Hepatitis B Virus.  HCV shall mean Hepatitis C Virus.  HPV shall mean Human Papilloma Virus.  First HPV Indication shall mean treatment or prevention of cervical dysplasias and neoplasia.

IPSCIO Record ID: 204323

License Grant
Korean Licensor grants an exclusive license, with the right to sublicense, under all Licensor Patent Rights and Know-How, including, without limitation, Licensors rights in Licensors Inventions, to develop, make, have made, use, register, offer to sell, sell, export and import the Compounds and Program Products in the Licenses Territory in the Anti-HBV Field.
License Property
The Program Product means any pharmaceutical formulation containing a Compound for administration to humans to treat chronic Hepatitis B Virus or HBV infection.

Hepatitis B virus, or HBV, infection is a growing global health problem that can cause both acute and chronic viral infections.

The patents are for Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.

IP relates to potential commercialization LB80380 (ANA380), a Phase II nucleotide analog for the treatment of chronic hepatitis B virus infection.

Field of Use
LB80380 (ANA380) is a nucleotide analog currently in Phase II clinical trials for the treatment of chronic HBV infection. The compound has exhibited activity in vitro against both HBV typically found in untreated patients and also HBV variants that demonstrate resistance to treatment with the nucleotide analog lamivudine, which is a currently commercialized therapy for HBV. Preclinical studies have demonstrated significant activity against HBV, low potential for drug interactions and good tolerability in a range of preclinical toxicology studies. Based on clinical trials to date, LB80380 (ANA380) appears to offer the potential for once daily dosing.

IPSCIO Record ID: 273462

License Grant
Licensor grants a worldwide, exclusive, and sublicensable right and license to practice the Licensor Technology and all of Licensors rights in Collaboration Patent Rights to make. have made. use. import, promote, market,  or sell Licensed Products in the Licensed Field.

Licensor grants a worldwide, exclusive or non-exclusive, as the case may be, and sublicenseable  right and license to practice the Third Party Technology to make, have made, use, import, promote, market, distribute or sell Licensed Products in the Licensed Field.

For the Grant of License to Joint Collaboration Patent Rights Outside the Licensed Field, Licensor grants a worldwide, non-exclusive, and sublicenseable right and license to practice Licensors rights in Joint Collaboration Patent Rights to make, have made, import, promote, market, distribute or sell products or processes outside the Licensed Field.

License Property
The Patent Rights and Know-How are pertaining to the PADRE® Technology.

Licensed Product shall mean a therapeutic or prophylactic vaccine the manufacture. use or sale of which, but for any license granted to Licensee herein, would infringe a Valid Claim of one or more Licensor Patent Rights or one or more Collaboration Patent Rights, or was developed or manufactured using Licensor Know-How.

PADRE® Technology shall mean a family of immunostimulatory molecules which when combined with cytotoxic T cell epitopes increase the magnitude and duration of the immune response.

Field of Use
Licensed Field shall mean the research, development and commercialization of Licensed Products for treating or preventing diseases associated with the following viruses HPV. HBV and HCV.  HBV shall mean Hepatitis B Virus.  HCV shall mean Hepatitis C Virus.  HPV shall mean Human Papilloma Virus.   First HPV Indication shall mean treatment or prevention of cervical dysplasias and neoplasia.

IPSCIO Record ID: 203459

License Grant
Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under Licensors interest in Collaboration Patents, and Collaboration Know-How, in each case solely to develop, make, have made, use, sell, have sold, offer for sale and import Products in the Field in the Territory; provided, however, that Licensor retains such rights under Collaboration Technology as are necessary to perform its obligations under the Research Program.

This agreement also includes Non-Exclusive Cross-Licenses where each Party hereby grants to the other Party a non-exclusive, royalty-free license, without the right to sub-license
(i) under such Partys interest in Collaboration Know-How for the manufacture or formulation of products other than Products, including 'cocktail' and other Combination Products; and
(ii) under such Partys interest in Collaboration Know-How, solely to conduct research in the HCV Field in the Territory.

License Property
Licensor has a research program for the discovery and optimization of nucleoside inhibitors of the NS5b polymerase in hepatitis C virus.

The Collaboration Compound shall mean a Nucleoside that satisfies the chemical and technical requirements set forth, and its Related Compounds and which
(a) is or was synthesized by or for Licensor on or before the Effective Date or during the Research Program Term; or
(b) is a Related Compound to a Collaboration Compound disclosed by Licensor to Licensee pursuant to Identification and Contribution of Collaboration Compounds and which is synthesized by or for Licensee after the Effective Date.

The Collaboration Compound Products shall mean any preparations in final form, bulk form or other form containing as an active pharmaceutical ingredient one or more Selected Compounds.

Field of Use
The Field shall mean all human and animal therapeutic, diagnostic, and prophylactic uses, including, without limitation, the treatment, prevention and prophylaxis of hepatitis C viral infections.

The HCV Field shall mean the treatment of chronic hepatitis C viral infections in humans.

The Collaboration Compound Products are for sale by prescription, over-the-counter or any other method, including without limitation any Combination Product.

IPSCIO Record ID: 303948

License Grant
Licensor assigns all of Licensor’s right, title and interest in the Assigned Patents and Assigned Know-How.

Licensor grants a non- exclusive, revocable, sublicenseable, nontransferable license, under the Licensed Know- How to Research, Develop, Manufacture, have Manufactured, use, keep, sell, offer for sale, import, export and Commercialize the Assigned Compounds and Products in the Field of Use in the Territory during the Term.

This agreement includes an exclusive grant back to Licensor.

License Property
Licensor owns rights to the proprietary compounds identified as VX-222 and VX-497.

VX-222 is an investigational HCV (Hepatitis C Virus) polymerase inhibitor.  Treatment with VX-222 resulted in mean reductions in plasma HCV RNA of greater than 3 log10.

VX-497, or merimepodib, is a drug for autoimmune diseases.

Field of Use
The field of use is the field of anti-infectives and anti-virals and the diagnosis, treatment, or prevention thereof.

VX-222 is for the oral Treatment of Hepatitis C.  VX-497, or merimepodib, is an oral treatment for HCV (Hepatitis C Virus) infection.  This agreement Field does not limit the use to HCV, but does limit the use to Anti-infectives and Anti-virals.

IPSCIO Record ID: 316064

License Grant
This amendment, updates the Licensees name to its successor, and, amends milestones and royalties.   In the original agreement,  Licensor grants a non- exclusive, revocable, sublicenseable, nontransferable license, under the Licensed Know- How to Research, Develop, Manufacture, have Manufactured, use, keep, sell, offer for sale, import, export and Commercialize the Assigned Compounds and Products in the Field of Use in the Territory during the Term.  The original agreement includes an exclusive grant back to Licensor.
License Property
The original agreement states Licensor owns rights to the proprietary compounds identified as VX-222 and VX-497.

VX-222 is an investigational HCV (Hepatitis C Virus) polymerase inhibitor.  Treatment with VX-222 resulted in mean reductions in plasma HCV RNA of greater than 3 log10.

VX-497, or merimepodib, is a drug for autoimmune diseases.

Field of Use
The original agreement states the field of use is the field of anti-infectives and anti-virals and the diagnosis, treatment, or prevention thereof.

VX-222 is for the oral Treatment of Hepatitis C.  VX-497, or merimepodib, is an oral treatment for HCV (Hepatitis C Virus) infection.  This agreement Field does not limit the use to HCV, but does limit the use to Anti-infectives and Anti-virals.

IPSCIO Record ID: 279369

License Grant
Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under Licensor Technology to Develop, make, have made, use, sell, have sold, offer for sale and import Compounds and Licensed Products in the Field in the Territory.

This agreement includes a non-exclusive grant back to Licensor.

License Property
Licensor has certain proprietary technology in compounds for the prevention and treatment of chronic hepatitis C infection.

The patents include Substituted Aryl Acylthioureas and Related Compounds Inhibitors of Viral Replication;
Heteroaryl Substituted Thioureas Inhibitors of Viral Replication;   Substituted Aryl Acylthioureas and Related Compounds Inhibitors of Viral Replication;  and, Substituted Arylthiourea Derivates Useful as Inhibitors of Viral Replication.

Compound means each of the following
—  inhibitors of HCV replication,  
—  any compound made pursuant to the Research Program with utility in the HCV Field or proven at a later date to have utility in the HCV Field; or,
—  any additional small molecules that are identified by either Party at any time prior to the end of the term of the Agreement, which can reasonably be demonstrated to inhibit HCV replication in replicon containing cells with a primary mechanism that results in abnormal processing of HCV proteins via HCV NS3 protease.

Field of Use
The Field means all human and animal therapeutic, diagnostic, and prophylactic uses, including, without limitation, the treatment, prevention and prophylaxis of hepatitis C viral infections.

HCV Field means the treatment of chronic hepatitis C viral infections in humans.

IPSCIO Record ID: 368651

License Grant
Licensor grants a worldwide, exclusive license to Licensor Patent Rights and Know-How to make, have made, use, import, offer to sell, and sell Product using Licensed Compound supplied by Licensor, or supplied by a third party, for use in the Field.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor, through its Drug Delivery Systems Division, has expertise and technology, with know-how and patents owned by Licensor, relating to toll-like receptor TLR 7 and/or 8 immune response modifier (IRM) compounds, formulations, conjugation, delivery, and manufacturing including proprietary IRM compounds such as resiquimod and others, that are useful as vaccine adjuvants.

The Compound is designated by Licensor as Resiquimod (R-848), S36212, 1-(4-aminobutoxy) -2-butyl-lH-imidazo (4,5-cl quinolin-4-amine and conjugates thereof.

Product shall mean any combination of a Licensee Antigen Presenting Cell or APC Targeting Technology vaccine with a Licensed Compound to be utilized as a Vaccine Adjuvant.

Vaccine Adjuvant shall mean a Licensed Compound which is used to induce, augment, fine-tune, enhance, or desensitize an antigen-specific immune response to an antigen contained in a vaccine or generated by a DNA vaccine for the therapeutic treatment of an existing disease or prophylactic use as protection against future disease, including desensitization to allergens. The antigen and the vaccine adjuvant may be admixed, delivered simultaneously, conjugated, or delivered separately, provided however, that the separate administration of the antigen and vaccine adjuvant is limited to the topical, dermal or mucosal or intradermal routes of administration and must be administered within 48 hours at substantially the same site and labeled as such by the applicable regulatory authority.

TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.

Field of Use
Licensor’s patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by Licensee to develop new vaccine products.  This license agreement provides a great opportunity to combine synergistic technologies designed to treat various cancers and infectious diseases.

The Field shall mean human prophylactic or therapeutic vaccination against any and all cancer disease states and selected infectious diseases.

This agreement focus is Cancer and the Infectious Diseases
– human immunodeficiency virus (HIV);
– human papillomavirus (HPV); and,
– hepatitis B virus (HBV).

IPSCIO Record ID: 227266

License Grant
The Licensor of Korea grants an exclusive option to enter into the License Agreement, exercisable during the Option Period.

For the Option to Negotiate, Licensor grants an exclusive option to negotiate with Licensor for a license in the Licensee Territory to the Compounds for purposes of treating HIV infection in humans (the HIV Option), exercisable during the Option Period.

For the scope of the License, Licensor grants exclusive rights, with the right to sublicense, under all Licensor Patent Rights and Know-How to develop, make, have made, use, register, offer to sell, sell, export and import the Compounds and Products in the Licensee Territory for purposes of treating chronic Hepatitis B Virus (HBV) infection in humans.

License Property
The compound is known as LB80380 for treating chronic Hepatitis B Virus (HBV) infection in humans, the compound designated LB80331, the compound designated LB80317, all salts, esters, prodrugs, intermediates and metabolites of LB80380, LB80331 or LB80317, any analogs or formulations as a human therapeutic for treatment of chronic HBV infection of LB80380, LB80331 or LB80317, whose manufacture, use, or sale would infringe a claim of an issued patent or pending application for a patent included in the Licensor Patent Rights; provided, however, that Licensor shall retain all rights to such analogs or formulations of LB80380, LB8033 l or LB80317 for all uses other than as a human therapeutic for treating chronic HBV infection; and all phosphorylated forms, tautomeric forms and steriochemical forms of either LB80380, LB80331 or LB80317.

Product means any pharmaceutical formulation for administration to humans to treat chronic HBV infection containing a Compound.

The patents are for Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same; (+)-trans-( I -phosphonometh oxy-2-alkyl cycolpropyl)methyl nucleoside.

Field of Use
The field of use is for treating chronic Hepatitis B Virus (HBV) infection in humans.

IPSCIO Record ID: 257474

License Grant
The original agreement is an exclusive license under Licensor patent rights and know-how to develop, make, have made, use and sell Licensed products in the Territory.
License Property
With this amendment, Licensed products shall also mean Treatment vaccines.  Treatment vaccines shall mean a bulk or finished vaccine.

The parties wish to further amend the Agreement to provide that Merck shall have rights to vaccine products for the treatment of patients infected with Human Immunodeficiency Virus and Hepatitis B Virus.

Field of Use
The field of use is for the treatment of Human Immunodeficiency Virus (HIV-1) and/or diseases caused by infection with HIV-I in humans and Hepatitis B Virus (HBV) and/or diseases caused by infection with HBV in humans, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.